Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback